1[1]Ylikorkala O,Lim P,Caubel P.Effects on serum lipid profiles of continu ous 17beta-estradiol,intermittent norgestimate regimens versus continuous combi ned 17beta-estradiol/norethisterone acetate hormone replacement therapy.Cline Ther,2000,22:622.
2[2]Mercuro G,Zoncu S,Piano D,et al.Estradiol-17β reduces blood pressure and res tores the normal amplitude of the circadian blood pressure rhythm in postmenopau sal hypertension.Am J Hypertens,1998,11:909.
3[3]Manwaring P,Morfis L,Diamond T,et al.Effects of hormone replacement therapy on ambulatory blood pressure and vascular responses in normotensive women.Blood P ress,2000,9:22.
4[4]Ceballos C,Ribes C,Amado JA,et al.Venous endothelial function in postmenopausa l women who are receiving long-term estrogen and progestagen therapy.Fertil St eril,2000,74:268.
5[5]Cagnacci A,Zanni AL,Veneri MG,et al.Influence of exogenous melatonin on catech olamine levels in postmenopausal women prior and during oestradiol replacement.C lin Endocrinol Oxf,2000,53:367.
6[6]Doren M,Rubig A,Coelingh B HJ,et al.Resistance of pelvic arteries and p lasma lipids in postmenopausal women:comparative study of tibolone and continuou s combined estradiol and norethindrone acetate replacement therapy.Am J Obster G ynecol,2000,183:575.
7[7]Westendorp IC,t-Veld BA,Grobbee DE,et al.Hormone replacement therapy and peri pheral arterial disease.Arch Intern Med,2000,11:160:2498.
8[8]Anderson TJ.Acute effect of estrogen on metabolic coronary vasodilator respons es to atrial pacing in postmenopausal women.Am J Cardiol,1998,82:236.
9[9]Heald A,Selby PL,White A,et al.Progestins abrogate estrogen-induced changes i n the insulin-line growth factor axis.Am J Obstet Gynecol,2000,183:593.
10[10]Manwaring P,Morfis L,Diamond T,et al.The effects of hormone replacement thera py on plasma lipids in type Ⅱ diabetes.Maturitas,2000,34:239.
